Skip to main content

NYSE:BVS - Bioventus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.50
  • Forecasted Upside: 33.11 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$14.65
▲ +0.1 (0.69%)
1 month | 3 months | 12 months
Get New Bioventus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BVS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.50
▲ +33.11% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Bioventus in the last 3 months. The average price target is $19.50, with a high forecast of $23.00 and a low forecast of $17.00. The average price target represents a 33.11% upside from the last price of $14.65.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in Bioventus.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2021Morgan StanleyBoost Price TargetOverweight$18.00 ➝ $19.00N/A
i
4/19/2021Morgan StanleyBoost Price TargetOverweight$18.00 ➝ $19.00Low
i
3/15/2021The Goldman Sachs GroupInitiated CoverageBuy$19.00Low
i
3/15/2021JPMorgan Chase & Co.Initiated CoverageOverweight$17.00Low
i
3/15/2021Morgan StanleyInitiated CoverageOverweight$18.00Low
i
3/15/2021Canaccord GenuityInitiated CoverageBuy$23.00Low
i
3/8/2021JPMorgan Chase & Co.Initiated CoverageOverweight$17.00High
i
3/8/2021Morgan StanleyInitiated CoverageOverweight$18.00High
i
3/8/2021The Goldman Sachs GroupInitiated CoverageBuy$19.00Medium
i
3/8/2021Canaccord GenuityInitiated CoverageBuy$23.00Medium
i
(Data available from 5/8/2016 forward)
Bioventus logo
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $14.65
$14.28
$14.84

50 Day Range

MA: $14.69
$13.75
$16.31

52 Week Range

Now: $14.65
$10.74
$19.51

Volume

32,229 shs

Average Volume

233,993 shs

Market Capitalization

$832.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bioventus?

The following Wall Street sell-side analysts have issued reports on Bioventus in the last twelve months: Canaccord Genuity, JPMorgan Chase & Co., Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for BVS.

What is the current price target for Bioventus?

4 Wall Street analysts have set twelve-month price targets for Bioventus in the last year. Their average twelve-month price target is $19.50, suggesting a possible upside of 33.1%. Canaccord Genuity has the highest price target set, predicting BVS will reach $23.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $17.00 for Bioventus in the next year.
View the latest price targets for BVS.

What is the current consensus analyst rating for Bioventus?

Bioventus currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BVS will outperform the market and that investors should add to their positions of Bioventus.
View the latest ratings for BVS.

What other companies compete with Bioventus?

How do I contact Bioventus' investor relations team?

The company's listed phone number is 919 474 6700. The official website for Bioventus is www.bioventus.com.